Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
Cooper
James E
JE
University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA.
Wiseman
Alexander C
AC
Chan
Laurence
L
D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006680:HLA Antigens / Q000097:blood; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood* / Q000187:drug effects; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000276:immunology*; D011719:Pyrazines / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology* / Q000473:pathology; D055815:Young Adult
D001897:Boronic Acids; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine